Solid Biosciences Inc. Operating Cash Flow
Solid Biosciences Inc. (SLDB) reported Operating Cash Flow of -$99.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Solid Biosciences Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$52.59M.
- Solid Biosciences Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$47.23M.
- Solid Biosciences Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$53.55M.
- Solid Biosciences Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$33.47M.
- Solid Biosciences Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$156.29M.
- Solid Biosciences Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$100.01M.
- Solid Biosciences Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$94.18M.
- Solid Biosciences Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$97.98M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$52.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$99.82M 10-Q · filed 2026-08-06 | -$153.37M derived: sum of 3 quarters · filed 2026-08-06 | -$186.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$47.23M 10-Q · filed 2026-05-12 | -$100.78M derived: sum of 2 quarters · filed 2026-05-12 | -$134.26M derived: sum of 3 quarters · filed 2026-05-12 | -$171.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$53.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$87.03M derived: sum of 2 quarters · filed 2026-03-19 | -$124.44M derived: sum of 3 quarters · filed 2026-08-06 | -$156.29M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$33.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$70.88M derived: sum of 2 quarters · filed 2026-08-06 | -$102.73M 10-Q · filed 2025-11-03 | -$132.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$37.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$69.26M 10-Q · filed 2026-08-06 | -$98.91M derived: sum of 3 quarters · filed 2026-08-06 | -$122.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$31.85M 10-Q · filed 2026-05-12 | -$61.49M derived: sum of 2 quarters · filed 2026-05-12 | -$85.20M derived: sum of 3 quarters · filed 2026-05-12 | -$106.67M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$29.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$53.35M derived: sum of 2 quarters · filed 2026-03-19 | -$74.82M derived: sum of 3 quarters · filed 2026-03-19 | -$100.01M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$23.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$45.17M derived: sum of 2 quarters · filed 2025-11-03 | -$70.37M 10-Q · filed 2025-11-03 | -$91.19M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$21.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$46.66M 10-Q · filed 2025-08-12 | -$67.48M derived: sum of 3 quarters · filed 2025-08-12 | -$85.38M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$25.19M 10-Q · filed 2025-05-15 | -$46.02M derived: sum of 2 quarters · filed 2025-05-15 | -$63.91M derived: sum of 3 quarters · filed 2025-05-15 | -$91.38M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$20.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$38.72M derived: sum of 2 quarters · filed 2025-03-06 | -$66.19M derived: sum of 3 quarters · filed 2025-03-06 | -$94.18M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$17.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$45.36M derived: sum of 2 quarters · filed 2024-11-06 | -$73.36M 10-Q · filed 2024-11-06 | -$107.84M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$27.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$55.46M 10-Q · filed 2024-08-13 | -$89.94M derived: sum of 3 quarters · filed 2024-08-13 | -$110.37M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$28.00M 10-Q · filed 2024-05-15 | -$62.48M derived: sum of 2 quarters · filed 2024-05-15 | -$82.90M derived: sum of 3 quarters · filed 2024-05-15 | -$98.78M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$34.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$54.91M derived: sum of 2 quarters · filed 2024-03-13 | -$70.79M derived: sum of 3 quarters · filed 2024-03-13 | -$97.98M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$20.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$36.31M derived: sum of 2 quarters · filed 2023-11-08 | -$63.50M 10-Q · filed 2023-11-08 | -$84.37M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | -$15.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$43.07M 10-Q · filed 2023-08-14 | -$63.94M derived: sum of 3 quarters · filed 2024-03-13 | -$82.37M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | -$27.19M 10-Q · filed 2023-05-11 | -$48.06M derived: sum of 2 quarters · filed 2024-03-13 | -$66.49M derived: sum of 3 quarters · filed 2024-03-13 | -$83.59M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | -$20.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$39.30M derived: sum of 2 quarters · filed 2024-03-13 | -$56.40M derived: sum of 3 quarters · filed 2024-03-13 | -$77.76M 10-K · filed 2024-03-13 |
| 2021-09-30 | -$18.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$35.52M derived: sum of 2 quarters · filed 2022-11-10 | -$56.89M 10-Q · filed 2022-11-10 | -$55.58M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | -$17.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$38.47M 10-Q · filed 2022-08-11 | -$37.16M derived: sum of 3 quarters · filed 2023-03-23 | -$52.72M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | -$21.37M 10-Q · filed 2022-04-27 | -$20.06M derived: sum of 2 quarters · filed 2023-03-23 | -$35.62M derived: sum of 3 quarters · filed 2023-03-23 | -$48.69M derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$14.26M derived: sum of 2 quarters · filed 2023-03-23 | -$27.32M derived: sum of 3 quarters · filed 2023-03-23 | -$56.60M 10-K · filed 2023-03-23 |
| 2020-09-30 | -$15.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$28.63M derived: sum of 2 quarters · filed 2021-11-03 | -$57.91M 10-Q · filed 2021-11-03 | -$79.15M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-06-30 | -$13.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$42.34M 10-Q · filed 2021-08-16 | -$63.59M derived: sum of 3 quarters · filed 2022-03-14 | -$82.83M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-03-31 | -$29.27M 10-Q · filed 2021-05-14 | -$50.52M derived: sum of 2 quarters · filed 2022-03-14 | -$69.76M derived: sum of 3 quarters · filed 2022-03-14 | -$96.06M derived: sum of 4 quarters · filed 2022-03-14 |
| 2019-12-31 | -$21.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$40.49M derived: sum of 2 quarters · filed 2022-03-14 | -$66.79M derived: sum of 3 quarters · filed 2022-03-14 | -$92.71M 10-K · filed 2022-03-14 |
| 2019-09-30 | -$19.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$45.54M derived: sum of 2 quarters · filed 2020-11-05 | -$71.47M 10-Q · filed 2020-11-05 | -$92.87M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | -$26.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$52.23M 10-Q · filed 2020-08-06 | -$73.63M derived: sum of 3 quarters · filed 2021-03-15 | -$88.92M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | -$25.93M 10-Q · filed 2020-05-07 | -$47.33M derived: sum of 2 quarters · filed 2021-03-15 | -$62.62M derived: sum of 3 quarters · filed 2021-03-15 | -$78.95M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | -$21.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | -$36.69M derived: sum of 2 quarters · filed 2021-03-15 | -$53.02M derived: sum of 3 quarters · filed 2021-03-15 | -$70.20M 10-K · filed 2021-03-15 |
| 2018-09-30 | -$15.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$31.62M derived: sum of 2 quarters · filed 2019-11-12 | -$48.79M 10-Q · filed 2019-11-12 | -$62.77M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$16.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$33.50M 10-Q · filed 2019-08-14 | -$47.48M derived: sum of 3 quarters · filed 2020-03-12 | -$56.92M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$17.17M 10-Q · filed 2019-05-13 | -$31.15M derived: sum of 2 quarters · filed 2020-03-12 | -$40.59M derived: sum of 3 quarters · filed 2020-03-12 | -$50.20M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$13.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$23.42M derived: sum of 2 quarters · filed 2020-03-12 | -$33.03M derived: sum of 3 quarters · filed 2020-03-12 | -$43.22M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$9.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$19.05M derived: sum of 2 quarters · filed 2018-11-13 | -$29.24M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$9.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | -$19.80M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | -$10.20M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | -$20.12M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |